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A stability-indicating micellar electrokinetic capillary chromatography (MEKC) method was developed and validated for the 
analysis of doxorubicin hydrochloride in injectable pharmaceutical dosage forms, using methotrexate as internal standard. A 
fused-silica capillary (50 µm i.d.; effective length, 40 cm) and a running electrolyte solution consisting of 10 mM borate buffer 
and 20 mM anionic surfactant SDS, at pH 9.3, were set as the best experimental conditions. Moreover, the capillary temperature 
was maintained at 26 ºC, while the applied voltage was +26 kV. Hydrodynamic sample injection (6 s at 50 mbar) was used, and 
the detection was set at 260 nm using a photodiode array detector. The method was validated for the requirements specificity, 
linearity, precision, accuracy, and robustness, following the International Conference on Harmonisation (ICH) guidelines. The 
method linearity was proven in the range of 25-125 µg/mL (r = 0.9995). Forced degradation studies were successfully conducted, 
evidencing the specificity and stability-indicating capability of the method. In addition, no interference of the excipients from the 
formulation was detected. The values of accuracy and precision were within the acceptable limits, and robustness studies were 
performed by a two-level full factorial design. The proposed method fulfilled all validation parameters and was shown to be 
suitable for quantitative analyses of doxorubicin, contributing, thus, to the establishment of new alternatives with advantages for 
the quality control of pharmaceutical formulations. 
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Introduction  
Doxorubicin (DOX), a member of the anthracycline ring 
antibiotics, is one of the considering first-line 
chemotherapeutic compounds, with suitable antitumor 
efficacy against a wide range of solid tumors. It is a 
hydrophilic drug, with mechanism of action consisting in 
binding to DNA by intercalation, with consequent induction 
of a series of biochemical events that lead to apoptosis in 
tumor cells (1,2). Cancer is one of the most common causes 
of death worldwide. Chemotherapy, although is considered 
the primary treatment for cancer among conventional 
modalities, displays many problems, such as low 
bioavailability, dose-limiting systemic toxicity and 
development of drug resistance (3). Even so, the 
administration of chemotherapies grows along with the 
growing number of patients with cancer. Therefore, the 
analytical control is extremely important to ensure the 
quality of the pharmaceutical formulations available for the 
treatment of cancer.  
Concerning analytical techniques available in the literature 
to determine DOX, the vast majority are about liquid 
chromatographic (LC) methods to quantify DOX in 
complexes biological matrices by fluorescence (4,5) or UV 
detector (6), as well as LC coupled to mass spectrometry 
(LC-MS) as a more sensitive methodology (7). With regard 
to the drug analysis in pharmaceutical formulations, besides 
the available monographs in the main pharmacopoeias 
worldwide describing LC-UV methods, there is also a 
methodology described by Sastry and Rao (8) based on 
complexes colorimetric reactions and spectrophotometric 
measurements. LC is a powerful analytical technique; 
however, comprises important solvent consumption, which 
resulted in a large volume of liquid waste contaminated with 
antineoplastic drugs. Likewise, the spectrophotometry might 
not attend the acceptable standards of sensitivity and 
specificity depend on the drug and/or formulation matrix.  
Capillary electrophoresis (CE) has appeared as a powerful 
analytical technique in the pharmaceutical area, with some 
advantages related to the existing analytical techniques (9). 
As well as the LC, the CE is a closed system, which is 
particularly suitable in terms of safety for handling toxic 
samples. Moreover, it is characterized by a markedly low 
solvent consumption and a high versatility (10). As one of 
the main disadvantages, is the low sensitivity attributed to 
the short optical path. However, for the analysis of drugs in 
pharmaceutical formulations, this is not a limitation, as 
solutions with enough concentrations can be prepared for the 
analysis. Some authors have reported capillary zone 
electrophoresis (CZE) or micellar electrokinetic capillary 
chromatography (MEKC) methods to quantify DOX 
especially in plasma samples. GAVENDA et al. (11) used 
CE method to determine two anthracyclines, doxorubicin 
and daunorubicin (DAU), by UV detection (190 – 260 nm) 
using a fused-silica capillary with 50 μm i.d. and 45 cm 
effective length, 100 mM phosphate buffer pH 2.5 added 
40% (v/v) methanol as background electrolyte and 150 mM 
SDS as a sweeping agent. The authors applied the method in 
samples of patient plasma. Moreover, CZE method was 
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developed and validated in a curve range of 0.1 – 100 
μg/mL to analyze DOX and liposomal DOX (Myocet®) in 
plasma samples, using potassium phosphate buffer (12.5 
mM, pH 7.4) and laser-induced fluorescence (LIF) detection 
(λex = 488 nm, λem = 630 nm) (12). Lu et al. (13) 
developed and validated a microchip-based CE method with 
LIF detection (λex = 469 nm, λem = 518 nm) using 10 mM 
sodium tetraborate buffer at pH 8.5 with 40% acetonitrile to 
separate DOX and DAU. The method was linear in 1-75 
μg/mL range and was applied to check the recovery ratio of 
these drugs in human serum sample. PÉREZ-RUIZ et al. 
(14) developed a CE method to separate the anthracyclines 
DOX, DAU and idarubicin in serum samples. The method 
used a fused-silica capillary 75 μm i.d. x 57 cm, 100 mM 
borate buffer pH 9.5 with 30% acetonitrile and appeared to 
be linear at 10-500 ng/mL range. MEKC was used to 
demonstrate the different metabolism between free and 
liposomal DOX (Doxil®) treating human leukemia cells. In 
this case, the buffer consisted of 20 mM γ-cyclodextrin, 50 
mM borate and 50 mM SDS at pH 9.3, with LIF detection 
(λex = 488 nm, λem = 635 nm) (15). In addition, a CE 
method was reported to assess DOX in pharmaceutical 
formulations; however, this method was focused in the 
analysis of multiple drugs in the same experimental 
procedure (10). Sixteen antineoplastic drugs were 
determined and DOX was assessed by CZE with UV 
detection, using a 100 mM phosphate buffer at pH 2.5 
containing 50% v/v of acetonitrile as background 
electrolyte, and dynamic coating of capillaries with Ceofix
®
.  
In view of these data, and considering that there is no 
published specific CE method for DOX determination in 
pharmaceutical formulations with UV detection, the 
objective of the present study was to develop and validate a 
stability-indicating MEKC method using UV-PDA 
detection, in accordance with ICH guidelines, as a tool to 
quantify DOX hydrochloride in injectable pharmaceutical 
dosage forms, with potential application in quality control 
analysis.  
 
Experimental 
Chemicals and reagents 
Doxorubicin hydrochloride (DOX, state purity 98.32%) 
was purchased from Zibo Ocean International Trade (Zibo, 
Shangdong, P.R., China) and methotrexate (MTX, state 
purity 100.1 %) was supplied by SM Empreendimentos 
Farmacêuticos Ltda (São Paulo, SP, Brazil). Different 
batches of Fauldoxo
®
 (Libbs Farmacêutica Ltda., 
Brazil) injectable pharmaceutical solutions, 
containing 2 mg/mL of doxorubicin 
hydrochloride, were obtained within their shelf 
life period. Sodium dodecyl sulfate (SDS) and analytical 
grade boric acid were acquired from Sigma-Aldrich (São 
Paulo, SP, Brazil) and Merck (Darmstadt, Germany), 
respectively. All chemicals used were of pharmaceutical or 
special analytical grade. For all analyses, ultrapure water 
was purified using a Mega RO/UP - Mega Purity system.  
Apparatus  
CE experiments were performed on an Agilent 7100 
Capillary Electrophoresis system (Agilent Technologies, 
Waldbronn, Germany) equipped with an autosampler, a 
1260 Infinity photodiode array (PDA) detector, a 
temperature controlling system (4-60 ºC) and power supply 
able to deliver up to 30 kV. A CE ChemStation software 
was used for instrument control, data acquisition and post 
run analysis of the electropherograms.  
Solutions 
Preparation of reference substance solutions  
An exactly weighed amount of DOX was transferred to a 
volumetric flask and diluted to volume with ultrapure water, 
obtaining a reference solution with final concentration of 2 
mg/mL. Methotrexate (MTX) solution, which was used as 
internal standard (IS), was prepared at a concentration of 1 
mg/mL using dimethylsulfoxide (DMSO). These stock 
solutions were kept in refrigerator, protected from light, and 
daily diluted to an appropriate concentration (75 µg/mL for 
both DOX and IS) with running electrolyte solution. 
Preparation of sample solutions 
A proper amount of injectable pharmaceutical preparation 
containing 2 mg/mL of doxorubicin hydrochloride was 
accurately transferred to a volumetric flask and diluted to 
the concentration 75 µg/mL with running electrolyte 
solution. IS stock solution was also added to reach a final 
concentration of 75 µg/mL. This sample solution was 
filtered through a 0.22 µm membrane filter (Millipore) and 
then injected into the EC system. 
Preparation of running electrolyte solution 
The running electrolyte solution was prepared by dissolving 
separately boric acid and SDS, both equivalent to 100 mM, 
in ultrapure water and kept in refrigerator. Each day, the 
boric acid and SDS stock solutions were further diluted in 
order to obtain a solution with 10 and 20 mM, respectively. 
The pH was adjusted to 9.3 by adding 1 M sodium 
hydroxide (NaOH). This solution was filtered through a 0.22 
μm. 
Electrophoretic procedure 
All experiments were carried out on a fused-silica capillary 
with 50 μm i.d. and 48.5 cm total length (effective length 40 
cm, Agilent), maintained at 26°C and with detection 
wavelength set at 260 nm. The capillary was daily 
conditioned with 1 M NaOH, ultrapure water and then the 
running electrolyte solution, each for 20 minutes. Between 
runs, the capillary was sequentially washed with 0.1 M 
NaOH (180 s), ultrapure water (180 s) and running 
electrolyte solution (240 s). With this treatment method, it 
was possible to achieve reproducible measurements and 
enhance the capillary column lifetime. The samples were 
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injected by hydrodynamic method (6 s at 50 mbar) and a 
constant voltage of +26 kV was applied during the analysis. 
After the last run of the experiments, the capillary was 
rinsed with 0.1 M sodium hydroxide, ultrapure water and 
finally dry cleaned. 
Validation of the method 
The method was validated using samples of injectable 
pharmaceutical formulation of doxorubicin hydrochloride 
with the label claim of 2 mg/mL by determinations of the 
following parameters: specificity, linearity, range, precision, 
accuracy, limit of detection (LD), limit of quantification 
(LQ), robustness, and system suitability test, following the 
International Conference on Harmonization (ICH) 
guidelines (16,17). Samples containing 75 µg/mL of both 
DOX and IS were used as work solutions during the 
validation process.  
Forced degradation studies  
The specificity and the stability-indicating capability of the 
method were evaluated by forced degradation studies in 
order to determine the potential interferences in the 
quantification of DOX. Solutions containing 1000 µg/mL of 
DOX were submitted to accelerated degradation in the 
following conditions: acidic and alkaline hydrolysis, heat, 
oxidant environment with hydrogen peroxide (H2O2) and 
UVC radiation. A sample solution prepared in 0.1 M 
hydrochloric acid (HCl) was used for the acidic hydrolysis, 
and a sample solution in 0.01 M NaOH for the alkaline 
hydrolysis evaluation. These solutions were incubated at 
room temperature for 24 h and 30 min, respectively, and 
neutralized with base or acid, as necessary. To study the heat 
effect in the DOX degradation profile, the drug solution was 
diluted in water and heated in an incubator at 80 ºC for 24 h. 
The oxidative degradation was achieved by storing the 
solutions in 3% hydrogen peroxide, at room temperature for 
24 h, protected from light. Photodegradation was induced by 
exposing the sample in a photostability chamber to UVC 
radiation for 24 h. The solutions were then diluted with the 
running electrolyte solution to a final DOX concentration of 
75 µg/mL. The drug content after each degradation 
condition was measured and the purity of both DOX and IS 
peaks was verified using a PDA detector (peak purity index 
higher than 0.999 was considered acceptable).  
Results and discussion 
Optimization of the electrophoretic conditions 
Optimization of the electrophoretic analysis was achieved 
by testing different methods based on CZE or MEKC 
separations. Initially, a CZE method was tested, 
investigating some electrolyte solutions containing sodium 
phosphate, boric acid, phosphoric acid or biological buffers 
such as TRIS and HEPES at different pH range (2.5 – 10.0). 
Indeed, it is well know that the DOX pKa is about 8.2 (18) 
and, thus, it can be expected that at least 50% of the drug 
would be ionized at this tested pH range. Nevertheless, no 
appreciable results were achieved to proceed with the 
method validation in none of the tested conditions. As a 
conclusion of these preliminary experiments, we opted to 
investigate the MEKC method using the surfactant SDS and 
borate buffer, which provided superior detector response and 
better analysis time in the first tests by the CZE method. 
Different running conditions were tested, such as buffer 
strength, applied voltage, pH, as well as buffer additives. 
The borate buffer and SDS concentration studied ranged 
from 10 to 30 mM and 10 to 50 mM, respectively, combined 
or not with an organic modifier. The addition of an organic 
modifier to the buffer has been reported to improve 
selectivity in MEKC (19). For this, we tested methanol or 
acetonitrile at small and different concentrations (5% - 
20%). Nevertheless, this option was excluded once these 
modifiers did not present any relevant improvements in the 
method optimization process. Different pH values for the 
running electrolyte solution were tested, ranging from 9.0 to 
10.0, while the applied voltage was evaluated in the range 
25 to 30 kV. From these studies, it was verified the 
gradually increase of the current as the buffer strength and 
voltage increases, as well as longer run times were obtained. 
Therefore, the use of 10 mM borate buffer at pH 9.3 and 
SDS 20 mM was considered the better condition for DOX 
analysis. It is noteworthy that similar buffers and pH range 
were used in studies mentioned elsewhere (13-15). The 
samples were injected hydrodynamically at 50 mbar for 6 s 
and the voltage applied was set at +26 kV (current about 13 
μA). A suitable separation performance was achieved within 
8.0 min, with a DOX migration time of 4.3 min, showing 
also good peak area, intensity, symmetry and resolution. 
This condition showed a shorter migration time than the 
method developed by Pérez-Ruiz et al. (14), in which DOX 
was detected at about 10 minutes, but longer than Lu et al. 
(13), due to the use of a microchip by the authors. The best 
detection wavelength was set as 260 nm and, even though it 
is not one that correspond to the maximum absorption, was 
chosen due to the suitable sensitivity to both DOX and IS 
(Figure 1), as well as lack of interferences from the 
formulation excipients (Figure 2).  
 
Figure 1. Absorption spectra where traces (1) and (2) correspond 
to DOX and MTX (IS), respectively.  
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Figure 2. Representative MEKC electropherograms where trace (a) 
represents placebo solution, (b) DOX reference substance solution 
(75 μg/mL), and (c) DOX pharmaceutical formulation (75 μg/mL). 
Peak 1 = internal standard (MTX) and peak 2 = DOX. 
The use of an IS is strongly recommended to compensate 
injection errors and minor fluctuations of the migration time 
during capillary electrophoresis analysis, thus improving the 
quantitative behavior. Then, some drugs, including 
nimesulide, furosemide and methotrexate, were tested, 
selecting methotrexate, another antitumor drug, which was 
found to be a suitable candidate, with a well resolved peak 
and good intensity. Figure 2 shows the typical 
electropherogram obtained with the optimized analytical 
conditions.  
Validation of the method 
The specificity of the method, which also determine the 
potential interference of the excipients of the pharmaceutical 
formulation, was evaluated by the analysis of placebo (an in-
house mixture of all excipients of the injectable solution 
without the active ingredient: sodium chloride, hydrochloric 
acid, sodium hydroxide and water for injection) (Figure 2). 
Moreover, the specificity of the method towards the drug 
was established through determination of peak purity of the 
analyte and the IS, obtained by overlay of the spectra 
captured at the apex, upslope and downslope using a PDA 
detector. Peak purity index values higher than 0.9998 
demonstrated that no formulation excipients were co-eluting 
with DOX, thus confirming that the proposed method is 
specific for the analysis of DOX in injectable 
pharmaceutical formulations. 
A stability-indicating method is as an analytical procedure 
that accurately quantifies the active molecule without 
interference from process impurities, excipients and/or 
degradation products. Therefore, stress testing of the drug 
substance can aid the identification of the potential 
degradation products, as well as to develop and validate the 
stability-indicating power of an analytical procedure (20). 
The forced degradation studies in neutral media followed by 
heat at 80ºC, as well as the photolytic condition, resulted in 
about 31 and 23% of drug degradation, respectively, with 
one eluting degradation product at the same migration time, 
of about 4 min (Figures 3a and b). Under the alkaline 
hydrolysis, DOX content exhibited a significant decrease 
after just 30 min of exposition, and one additional resolved 
peak was detected at 3 min (Figure 3c). In contrast, the 
acidic condition, only 12% of DOX degradation was 
observed after 24h and no additional peak was detected in 
the electropherogram (Figure 3d), indicating that the 
degradation products did not migrate in the MEKC method 
or may have been degraded to nonchromophoric products. 
Finally, the oxidative condition also exhibited decrease of 
the area, with three additional peaks detected at about 3, 4 
and 7.8 min (Figure 3e). Table 1 shows the percentage of 
drug degradation for each stress condition. Peak purity 
analysis were also performed in all tested stress conditions, 
and acceptable values (> 0.9998) were obtained for both 
DOX and IS peaks. 
 
Figure 3. Typical MEKC electropherograms of DOX solution (75 
μg/mL) after degradation under (a) neutral hydrolysis followed by 
heat at 80ºC, (b) photolytic condition, (c) alkaline hydrolysis, (d) 
acidic hydrolysis, and (e) oxidative condition. Peaks 1 to 6 
correspond to DOX degraded forms.  
Table 1. Amount of DOX degraded in each stress condition  
Condition DOX degradationa 
(%) ± SDb 
RSDc (%) 
0.01 M NaOH for 0.5 h 37.05 ± 2.28 5.12 
0.1 M HCl for 24 h 12.36 ± 1.96 3.16 
UVC radiation for 24 h 23.17 ± 4.77 6.78 
Oxidation with H2O2 for 
24 h 
27.07 ± 3.28 6.37 
Neutral hydrolysis at 80ºC 
for 24 h 
31.32 ± 8.79 6.10 
a Mean of three replicates 
b SD: Standard deviation 
c RSD: Relative standard deviation 
Linearity was determined by constructing three independent 
analytical curves in the range of 25-125 µg/mL prepared in 
running electrolyte solution. Three replicate injections of 
each reference solution spiked with MTX (75 µg/mL) as IS, 
were made to verify the repeatability of the detector 
response. The peak area ratio of DOX to the IS, against the 
respective reference concentrations, was used for plotting 
the graph, and the linearity evaluated by the least square 
regression analysis. The MEKC method was linear (r = 
0.9995, y = 0.0142x + 0.0179, where x is concentration of 
DOX expressed in μg/mL and y is the peak area ratio of 
DOX to IS).  
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The LD and LQ were calculated by using the mean of the 
slope (S) and the standard deviation of the intercept (σ) of 
three independent analytical curves, determined by a linear 
regression model, as defined by ICH (16). The theoretical 
values obtained were 4.60 and 15.32 μg/mL, for LD and LQ, 
respectively. Even though these parameters are not a 
requirement for drug assay, they are certainly important to 
evidence the method sensitivity.  
The precision of the method was determined by repeatability 
(intra-day precision) and intermediate precision (inter-day 
and between-analysts precision), and the experimental 
results were expressed as relative standard deviation (RSD). 
Repeatability was examined by calculating the RSD of assay 
results (%) of six independent sample preparations at 75 
µg/mL. The intermediate precision was assessed by 
analyzing three samples of the pharmaceutical formulation 
on two different days (inter-days) and by a second analyst 
(between-analysts). The precision results showed all RSD 
values lower than 2.0 %, as shown in Table 2, demonstrating 
that the method variability was within the acceptable range.  
 
Table 2. Repeatability ǂ, intermediate precision § and accuracy data 
of MEKC method for doxorubicin analysis in samples of injectable 
pharmaceutical formulations. 
 Precision   
 Assay ± SDa RSDb (%) 
Intra-day (n = 6) 99.76 ± 1.279 1.28 
Inter-day   
Day 1 (n = 3) 101.47 ± 0.783 0.77 
Day 2 (n = 3) 102.47 ± 1.576 1.54 
Mean (n = 6) 101.97 ± 0.708 0.69 
Between-analysts   
Analyst 1 (n = 3) 102.47 ± 1.576 1.54 
Analyst 2 (n = 3) 104.11 ± 0.679 0.65 
Mean (n = 6) 103.29 ± 1.158 1.12 
 Accuracy  
 Recovery ± SD RSD (%) 
60 µg/mL 101.79 ± 0.002 0.23  
75 µg/mL 101.27 ± 0.002 0.17 
90 µg/mL 99.22 ± 0.012 0.77  
Mean 100.76 ± 1.36 1.35 
ǂ intra-day 
§ inter-day and between-analysts 
a SD: Standard deviation 
b RSD: Relative standard deviation 
The accuracy was evaluated by the recovery of known 
amounts of reference solution, added to a sample solution, to 
obtain solutions at concentrations of 60, 75, and 90 μg/mL, 
equivalent to 80, 100, and 120%, of the analytical 
concentration (75 μg/mL), respectively. The accuracy was 
calculated at each concentration level from differences 
between the responses obtained for spiked and unspiked 
solutions. The absolute recovery values obtained for DOX 
are shown in Table 2, with a satisfactory mean percentage of 
100.76%, evidencing, thus, the accuracy of the method 
within the desired range. 
The robustness was assessed by evaluating the capability of 
the method to remain unaffected by small, but deliberate, 
modifications in some of the methods settings. A two-level 
full factorial design (number of analyses equal to 2
k
 + n, 
where k is the number of factors and n is the number of 
central points) was performed using Minitab v.17 software 
(Minitab Inc., State College, PA, USA). Here, a 2
3
 full 
factorial was applied, by analyzing samples after small 
changes in one, two or all of the following factors: borate 
buffer concentration in the electrolyte solution (8 and 12 
mM), capillary temperature (24 and 28 ºC) and voltage 
applied (24 and 28 kV). Therefore, second- and third-order 
interactions were evaluated (21). The analysis of the DOX 
reference and sample solutions containing 75 μg/mL were 
carried out in each combination, in a randomized order. The 
results were expressed as a Pareto chart (Figure 4), which 
shows that the single factors or their combinations did not 
significantly influence the analytical performance, since the 
bars did not cross the vertical line (critical t-value for α = 
0.05). Moreover, there were non-significant changes of the 
migration time and peak area ratios, as well as of the 
electropherogram pattern, in comparison to the optimized 
conditions, indicating that the proposed method is robust 
under the conditions tested. 
 
Figure 4. Pareto chart of the robustness evaluation of the MEKC 
method. The horizontal columns represent the main factors and 
their combinations. The vertical line indicates the critical t-value. 
A system suitability test was also carried out to evaluate the 
adequate performance and reproducibility of the system for 
the analysis to be executed, using six replicates injections of 
a reference substance solution containing 75 µg/mL of DOX 
and IS. The RSD values calculated for the migration time 
and peak area were 1.74 and 1.82%, respectively. The 
number of theoretical plates and peak symmetry were about 
27597 and 1.03, with RSD of 1.65 and 1.05%, respectively. 
The resolution between DOX and IS peaks was 16.48, with 
RSD of 1.35%. Altogether, the experimental data showed 
that the parameters tested were within the acceptable range 
(RSD < 2.0%), indicating that the method is suitable for the 
analysis intended. 
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Method application 
The validated MEKC method was applied for the 
determination of DOX in four different batches of an 
injectable pharmaceutical formulation. All batches showed 
mean content value in the range of 101.0 to 103.0%, with 
RSD lower than 1.0%. Therefore, the proposed method can 
be useful for the determination of DOX in injectable 
formulations, without prior separation of the excipients, with 
advantages of small sample volumes, short analysis time and 
no consumption of organic solvents, with the exception of a 
small amount of DMSO used to prepare the stock solution of 
the internal standard MTX.  
Conclusion 
The results of the validation studies show that the MEKC 
method is specific and stability-indicating. It possesses 
appropriate linearity, together with precision and accuracy 
within the acceptable limits. A full factorial design was 
successfully applied to assess robustness with many 
advantages over the traditional one-variable-at-time 
approach. The proposed method was also effectively applied 
for the quantitative analysis of doxorubicin in injectable 
pharmaceutical formulations, representing, thus, a simple 
and environment-friendly alternative for the quality control 
laboratory. 
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